Eutropics Information

Eutropics Pharmaceuticals, Inc. is developing PRIMAB-Dx, a clinically deployable functional biomarker platform that directly measures cancer cell survival dependencies on BCL-2 family proteins to guide apoptosis-targeted therapies in AML and other hematologic malignancies. Unlike research-grade functional assays, PRIMAB-Dx is being validated within a CLIA framework with a clear RUO-to-CLIA revenue model, making it immediately deployable for pharma partners running BH3 mimetic and apoptosis-targeted clinical trials. The platform addresses the critical unmet need of matching therapy to a patient's actual tumor physiology — not simply their disease classification. The company was founded by Michael Cardone, Ph.D. and a team of scientific founders and advisors with deep expertise in oncology drug and biomarker development, including Michael Andreeff, M.D., Ph.D. (MD Anderson), Alan D'Andrea, M.D. (Dana-Farber/Harvard), and Kevin Kelly, M.D. (USC Keck School of Medicine). Eutropics has raised over $21 million in non-dilutive grants, angel investment, and revenues, and maintains active research collaborations with MD Anderson Cancer Center, USC Keck School of Medicine, Massachusetts General Brigham, and the National University of Singapore. Eutropics is seeking venture-philanthropy investors who see the opportunity to underpin functional precision oncology across multiple drug portfolios with a scalable, revenue-generating diagnostic platform — delivering both patient impact and financial return. www.eutropics.com